Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27143651 | 0.90 | SMN1; SMN2 (0.42) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL29214298 | 0.89 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL29223471 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL18852406 | 0.86 | PIK3CD (0.58) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL31042676 | 0.86 | CYP2D6 (0.55) | USP2SMN1; SMN2MAPK1DPP4GPR119 | |
| SCHEMBL4539070 | 0.85 | HPGD (0.45) | USP2SMN1; SMN2CHRM1ALDH1A1HTT | |
| SCHEMBL29101928 | 0.85 | ABCB1 (0.52) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL16825817 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL20232006 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL27145793 | 0.84 | ABCB1 (0.42) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| CN-117120443-A | Compounds as adenosine A2a receptor antagonists and pharmaceutical compositions containing the same | 株式会社 钟根堂 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023097187-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-4019518-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3110820-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015131080-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| EP-2356113-B1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER IP GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2356113-B1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER IP GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-2356113-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010054763-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054763-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | USP2 390/4885SMN1; SMN2 2280/4885CHRM2 3384/4885 |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | USP2 2100/4885SMN1; SMN2 1145/4885CHRM2 4803/4885 |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | USP2 1260/4885SMN1; SMN2 2937/4885CHRM2 4040/4885 |
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | USP2 2042/4885SMN1; SMN2 4248/4885CHRM2 4793/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | USP2 3619/4885SMN1; SMN2 3477/4885CHRM2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.